Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI

"James Zou's EchoNet, a deep learning model for cardiac function assessment from echocardiograms, was cleared by the FDA after a blinded randomised clinical trial showed it outperformed human sonographers."

"His Virtual Lab, published in Nature in July 2025, assembled a team of large language model agents led by an AI principal investigator that designed 92 novel nanobody binders against SARS-CoV-2 variants, two of which showed improved binding in experimental validation."

"The Virtual Biotech framework created by Zou mimicked a pharmaceutical company's hierarchy with 11 specialised agents that spawned 37,000 sub-agents to annotate nearly 56,000 clinical trials, finding that drugs targeting cell-type-specific genes are 48% more likely to reach market."

James Zou is reportedly raising around $100 million for a startup named Human Intelligence, aiming for a $1 billion valuation. His research includes FDA-cleared cardiac AI, a Virtual Lab that designed novel nanobodies, and a multi-agent framework that annotated 56,000 clinical trials. Zou's AI systems have shown significant advancements in drug discovery and cardiac function assessment. The funding environment is favorable, with $11 billion invested in AI drug discovery in Q1 2026. The credibility of Zou's research underpins the startup's potential success.

Read at TNW | Artificial-Intelligence